Showing results (81-90 of 172) with videos related to

Sort By:
Pageof 18
Scientific Reports|June 17, 2015
CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcomaYan Gao, Yong Feng, Jacson K Shen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 9, 2024
Safety and Efficacy of the Combination Lurbinectedin plus Doxorubicin from a Phase 1b Trial in Patients with Advanced/Metastatic Soft-Tissue SarcomaGregory M Cote, Candace L Haddox, Edwin Choy, et al.
Journal of Surgical Oncology|December 31, 2013
MRI surveillance following treatment of extremity soft tissue sarcomaMatthew D Cheney, Christine Giraud, Saveli I Goldberg, et al.
Journal of Surgical Oncology|January 26, 2016
Prognostic factors in alveolar soft part sarcoma: A SEER analysisHaotong Wang, Alex Jacobson, David C Harmon, et al.
British Journal of Pharmacology|November 26, 2015
NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) functionShunan Ye, Jianming Zhang, Jacson Shen, et al.
European Journal of Cancer (Oxford, England : 1990)|January 4, 2020
A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomasGregory M Cote, Edwin Choy, Tianqi Chen, et al.
BMC Cancer|September 20, 2014
A-770041 reverses paclitaxel and doxorubicin resistance in osteosarcoma cellsZhenfeng Duan, Jianming Zhang, Shunan Ye, et al.
The Annals of Thoracic Surgery|December 21, 2020
Programmed Death Ligand 1 and Immune Cell Infiltrates in Solitary Fibrous Tumors of the PleuraLuis F Tapias, Mari Mino-Kenudson, Edwin Choy, et al.
Pageof 18